Page 835 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPtEr 58 Small- and Medium-Vessel Primary Vasculitis 807

management of adults with ANCA-associated vasculitis. Rheumatology 88. Martinez Del Pero M, Walsh M, Luqmani R, et al. Long-term damage to
(Oxford) 2014;53(12):2306–9. the ENT system in Wegener’s granulomatosis. Eur Arch Otorhinolaryngol
79. Ponte C, et al. Optimisation of vasculitis disease assessments in clinical 2011;268(5):733–9.
trials, clinical care and long-term databases. Clin Exp Rheumatol 89. Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular
2014;32(5 Suppl. 85):S-118-25. events in patients with newly diagnosed Wegener’s granulomatosis and
80. Mukhtyar C, G L, Cid MC, et al. BSR and BHPR Standards, Guidelines microscopic polyangiitis. Arthritis Care Res (Hoboken)
and Audit Working Group BSR and BHPR guideline for the management. 2011b;63(4):588–96.
Ann Rheum Dis 2009;68:310–17. 90. Shang W, Ning Y, Xu X, et al. Incidence of Cancer in ANCA-Associated
81. Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and Vasculitis: A Meta-Analysis of Observational Studies. PLoS ONE
cyclosporine A for maintenance of remission in Wegener’s 2015;10(5):e0126016.
granulomatosis-a clinical randomized controlled trial. Nephrol Dial 91. Basu N, McClean A, Harper L, et al. Markers for work disability in
Transplant 2011;26(1):206–13. anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology
82. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for (Oxford) 2014;53(5):953–6.
the management of primary small and medium vessel vasculitis. Ann 92. Walsh M, Mukhtyar C, Mahr A, et al. Health-related quality of life in
Rheum Dis 2009;68(3):310–17. patients with newly diagnosed antineutrophil cytoplasmic
83. Walsh M, Casian A, Flossmann O, Westman K, et al. Long-term follow-up antibody-associated vasculitis. Arthritis Care Res (Hoboken)
of patients with severe ANCA-associated vasculitis comparing plasma 2011;63(7):1055–61.
exchange to intravenous methylprednisolone treatment is unclear. Kidney 93. Suka M, Hayashi T, Kobayashi S, et al. Improvement in health-related
Int 2013;84(2):397–402. quality of life in MPO-ANCA-associated vasculitis patients treated with
84. Flossmann O, Berden A, de Groot K, Hagen C, et al. Long-term patient cyclophosphamide plus prednisolone: an analysis of 18 months of
survival in ANCA-associated vasculitis. Ann Rheum Dis follow-up data from the JMAAV study. Mod Rheumatol
2011;70(3):488–94. 2012;22(6):877–84.
85. Hoffman GS, Kerr G, Leavitt RY, et al. Wegener granulomatosis: an 94. Fujimoto SWR, Kobayashi S, Suzuki K, et al. Comparison of the
analysis of 158 patients. Ann Intern Med 1992;116:488–98. epidemiology of anti-neutrophil cytoplasmic antibody-associated
86. Hruskova Z, Stel V, Jayne D, et al. Characteristics and Outcomes of vasculitis between Japan and the U.K. Rheumatology (Oxford)
Granulomatosis With Polyangiitis (Wegener) and Microscopic 2011;50(10):1916–20.
Polyangiitis Requiring Renal Replacement Therapy: Results From the 95. Chen M, et al. Propylthiouracil-induced antineutrophil cytoplasmic
European Renal Association-European Dialysis and Transplant antibody-associated vasculitis. Nat Rev Nephrol 2012;8(8):476–83.
Association Registry. Am J Kidney Dis 2015;66(4):613–20. 96. Makino N, Nakamura Y, Yashiro M, et al. Descriptive epidemiology of
87. Suppiah R, Hadden R, Batra R, et al. Peripheral neuropathy in Kawasaki disease in Japan, 2011-2012: from the results of the 22nd
ANCA-associated vasculitis: outcomes from the European Vasculitis Study nationwide survey. J Epidemiol 2015;25(3):239–45.
Group trials. Rheumatology (Oxford) 2011;50(12):2214–22.